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Abstract
Background: Nipah virus (NiV) is a recently emerged paramyxovirus capable of causing fatal disease in a broad
range of mammalian hosts, including humans. Together with Hendra virus (HeV), they comprise the genus
Henipavirus in the family Paramyxoviridae. Recombinant expression systems have played a crucial role in studying
the cell biology of these Biosafety Level-4 restricted viruses. Henipavirus assembly and budding occurs at the
plasma membrane, although the details of this process remain poorly understood. Multivesicular body (MVB)
proteins have been found to play a role in the budding of several enveloped viruses, including some
paramyxoviruses, and the recruitment of MVB proteins by viral proteins possessing late budding domains (L-
domains) has become an important concept in the viral budding process. Previously we developed a system for
producing NiV virus-like particles (VLPs) and demonstrated that the matrix (M) protein possessed an intrinsic
budding ability and played a major role in assembly. Here, we have used this system to further explore the budding
process by analyzing elements within the M protein that are critical for particle release.
Results: Using rationally targeted site-directed mutagenesis we show that a NiV M sequence YPLGVG is required
for M budding and that mutation or deletion of the sequence abrogates budding ability. Replacement of the native
and overlapping Ebola VP40 L-domains with the NiV sequence failed to rescue VP40 budding; however, it did
induce the cellular morphology of extensive filamentous projection consistent with wild-type VP40-expressing
cells. Cells expressing wild-type NiV M also displayed this morphology, which was dependent on the YPLGVG
sequence, and deletion of the sequence also resulted in nuclear localization of M. Dominant-negative VPS4
proteins had no effect on NiV M budding, suggesting that unlike other viruses such as Ebola, NiV M accomplishes
budding independent of MVB cellular proteins.
Conclusion: These data indicate that the YPLGVG motif within the NiV M protein plays an important role in M
budding; however, involvement of any specific components of the cellular MVB sorting pathway in henipavirus
budding remains to be demonstrated. Further investigation of henipavirus assembly and budding may yet reveal a
novel mechanism(s) of viral assembly and release that could be applicable to other enveloped viruses or have
therapeutic implications.
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Background
Nipah virus (NiV) and Hendra virus (HeV) are emerging
members of the family Paramyxoviridae  that are distin-
guished by their ability to cause fatal disease in both ani-
mal and human hosts, and comprise the genus
Henipavirus [1,2]. HeV was recognized as a novel para-
myxovirus in 1994 during an outbreak in eastern Australia
that resulted in the death of one human as a consequence
of virus transmission from infected horses. Another per-
son later died from relapsed encephalitis as a result of HeV
infection that was identified retrospectively [3]. Repeated
HeV spillover events have since occurred five times, all
involving horses, with the most recent occurrence in July
2008 which also involved two human cases, one of which
was fatal [4,5]. NiV was identified during an outbreak of
severe encephalitis in Malaysia and Singapore that began
in 1998 and continued into 1999. In contrast to the HeV
outbreak, this NiV episode involved hundreds of people
and more than 100 deaths, with pigs serving as the inter-
mediate amplifying host [6,7]. Since 1998 there have been
9 recognized occurrences of NiV infection of people, pri-
marily in Bangladesh and India with the most recent in
March 2008 [8-14]. The mortality in humans has been
higher (~75%) in these spillover events, along with evi-
dence of human-to-human transmission and the appar-
ent lack of an intermediate host [8,15-17].
Several species of fruit bats (flying foxes) of the Pteropus
genus serve as the primary natural reservoirs of HeV and
NiV, although to date evidence of henipavirus infection in
5 other bat species across 5 genera has been reported
(reviewed in [5]). NiV has been isolated from bat urine
and partially eaten fruit, which suggests that it is relatively
easy to obtain from the environment [18,19]. Indeed,
direct transmission of NiV from flying foxes to humans
from contaminated food sources has been suggested
[9,20]. The Centers for Disease Control and Prevention
(CDC) and the National Institute of Allergy and Infec-
tious Diseases (NIAID) have classified HeV and NiV as
priority pathogens, and work with live virus requires
Biosafety Level-4 (BSL-4) containment.
Paramyxoviruses are enveloped viruses that replicate in
the cytoplasm and contain a genome consisting of single-
stranded negative-sense RNA [21]. The genome contains 6
principle genes: nucleocapsid (N), phosphoprotein (P),
matrix (M), the fusion (F) and attachment (HN, H, or G)
proteins, and the polymerase (L), along with accessory
proteins that vary according to viral species [21]. The
requirement for high containment conditions for working
with live HeV or NiV has necessitated the development of
recombinant protein expression systems as tools for eluci-
dating details of the henipavirus life cycle. We previously
established a virus-like particle (VLP) system in order to
study the assembly and budding process of NiV, and
determined that the M protein plays a central role in NiV
assembly [22]. We also observed that expression of M
alone resulted in the release of VLPs, as was also reported
by Ciancanelli and Basler [22,23]. Other paramyxovirus
M proteins with this property include Sendai virus (SeV)
[24,25], human parainfluenza virus type 1 (hPIV-1) [26],
and Newcastle disease virus (NDV) [27]. In contrast, sim-
ian virus 5 (SV5) (parainfluenza virus 5 (PIV5)) [28]
requires expression of M along with N and either F or HN
to produce VLPs [29]. The mechanism(s) that govern the
budding of M remain unknown. A current area of interest
in enveloped virus assembly and morphogenesis is the
contribution of L-domains, which are protein motifs first
identified in retroviral Gag precursor molecules that are
important for late steps in assembly and budding
(reviewed in [30-32]). L-domains interact with compo-
nents of cellular machinery involved in multivesicular
body (MVB) formation and are thought to commandeer
those proteins for use in viral budding. The involvement
of L-domains in virus assembly and budding has been
extended to other enveloped virus families including are-
naviruses [33], filoviruses [34,35], rhabdoviruses [35-37],
and paramyxoviruses [38,39]. In certain cases, different L-
domains can be functionally interchanged or mediate
their activity in a position-independent manner within
the protein molecule; however, these properties are not
universal and it is now apparent that the surrounding
regions or context within which the L-domain motif lies
can be important for its function [31,40-42]. There are
several well-characterized examples where the mutation
or removal of a viral L-domain motif within, for example,
the M protein, will abrogate the protein's ability to bud
from expressing cells [35,38,43-45].
L-domain amino acid motifs that have been identified
(along with the MVB protein each interacts with) include:
P(T/S)AP (Tsg101), PPxY (Nedd4-like E3 ubiquitin
ligases), YP(x)nL (AIP1/Alix), and ØPxV (none identi-
fied), where x is any amino acid and Ø is any aromatic
amino acid [30-32]. Until the identification of the novel
FPIV sequence in SV5 M [38], paramyxoviruses were not
known to utilize L-domains in their assembly and mor-
phogenesis. However, the M protein of many paramyxo-
viruses, including NiV and HeV, do not contain any
identified L-domains, including the SV5 FPIV motif [38].
The MVB protein AIP1/Alix was shown to help facilitate
SeV virion and VLP release through interactions with an
undetermined sequence in the C protein, as well as
through a recently identified YLDL sequence in the M pro-
tein [39,46]; however, a conflicting study failed to find a
role for AIP1/Alix in SeV virion production [47]. Cian-
canelli and Basler reported that NiV M contains a
sequence, YMYL, that is required for VLP budding and,
based on its ability to complement Ebola VP40 VLP for-Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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mation, suggested that this sequence serves as an L-
domain [23].
In this study, we report the identification of an amino acid
sequence motif (YPLGVG) that is required for NiV and
HeV M budding, and that appeared to partially comple-
ment the native Ebola VP40 phenotype but was VPS4-
independent. However, complementation of the Ebola
VP40 mutant was observed only in its effects on cellular
morphology, characterized by extensive filamentous pro-
jections, and not in Ebola VP40 budding. In addition,
cells expressing wild-type NiV M were noted to have a cel-
lular morphology similar to that of VP40 expressing cells,
and deletion of the YPLGVG sequence resulted in abroga-
tion of this morphology and nuclear localization of M.
Results
Mutation of the YPLGVG motif in NiV matrix abrogates 
budding
Most L-domains described to date contain one or more
proline residues. Because the NiV M protein does not con-
tain any of the exact known L-domain motifs, we exam-
ined the entire M protein sequence for proline residues
with surrounding amino acids that we considered to be
similar to known L-domains. Following this analysis, we
identified 3 sequences of interest with the intent of mutat-
ing the proline residues within these putative motifs to
alanine (Fig. 1A and 1B). Residue P35 was targeted
because it aligned closely to the SV5 FPIV (ØPxV) motif,
although there were no further sequence similarities. P93
is located in a sequence similar to the YP(x)nL motif, and
the P329 and P332 residues were targeted because of
sequence similarity to the P(T/S)AP motif. It was also
noted that P93, P329 and P332 are all well conserved
among paramyxovirus M proteins but are absent in SV5 M
(Fig. 1A), which further suggested that these proline resi-
dues might be part of an L-domain.
The mutant M gene cassettes were expressed in cells, pel-
leted through a 10% sucrose cushion, and analyzed by
immunoprecipitation and SDS-PAGE followed by autora-
diography. The result of this comparison revealed that
each of the mutant M proteins retained budding ability
except for the P93A mutant, which exhibited a marked
reduction in M protein release (Fig. 1C). The P93 residue
is part of an amino acid sequence (YPLGVG) that resem-
bles the YP(x)nL motif and also contains residues that are
well conserved among paramyxovirus M proteins (Fig.
1A). To confirm this observation and further characterize
the role of this sequence in M protein release, additional
M mutants were constructed: Y92A, L94A, and Δ92–97
(Fig. 2A), that were then tested in the budding assay. The
result of this experiment revealed that none of the addi-
tional mutant M proteins, with the exception of the P93A
mutant, which sometimes retained a low level of budding
activity, were released from expressing cells (Fig. 2B). All
of the mutants were expressed at levels similar to wild-
type NiV M, and these findings confirm the importance of
this motif. We previously observed that HeV M is also
released into the culture supernatant when expressed
alone, although less efficiently than NiV M (unpublished
observation). To determine whether the conserved
YPLGVG sequence is required for HeV M release, we con-
structed HeV M P93A and Δ92–97 mutants and tested
them in the budding assay. In contrast to wild-type HeV
M, which was released into the supernatant, we did not
detect release of the P93A mutant (Fig. 2C). We were una-
ble to detect expression of HeV M Δ92–97 (data not
shown), possibly due to mis-folding and degradation.
These data suggest that the YPLGVG sequence is required
for NiV and HeV M budding, and may also play a role in
HeV M stability.
The YPLGVG matrix motif can partially restore a defective 
VP40 phenotype
A notable feature of most viral L-domain motifs is their
inherent transferability to other M proteins defective in
budding [31,38,44]. Therefore, we sought to determine
whether this newly identified NiV M sequence could
impart budding activity within the context of a different
viral background. The Ebola VP40 protein contains two
overlapping L-domain motifs, the PTAPPEY sequence,
and deletion of these L-domains renders the protein
defective in release [35]. A VP40 mutant was constructed
in which we replaced the native L-domains and flanking
residues with the NiV M protein YPLGVG motif (Fig. 3A),
and this mutant was tested for budding activity. The
results of this experiment revealed that, although some
budding was evident, the NiV M sequence failed to rescue
VP40 budding above the basal level observed for the VP40
deletion mutant (data not shown). However, immunoflu-
orescent confocal microscopy revealed that cells express-
ing VP40-NiV that contained the YPLGVG motif had a
similar morphology to those expressing wild-type VP40,
which was characterized by extensive filamentous projec-
tions that were frequently branching and fragmented (Fig.
3B). Martin-Serrano and co-workers, as well as others, pre-
viously observed this phenotype in cells expressing VP40
[41,48,49]. This cellular morphology was not observed
when the native overlapping L-domains were deleted
from VP40 (VP40 ΔPT/PY) (Fig. 3B). However, cells
expressing wild-type NiV M showed a filamentous pheno-
type similar to those expressing VP40 (Fig. 4). In contrast,
the NiV M Δ92–97 mutant, that was totally defective in
budding, had an absence of the filamentous structures
and appeared to localize at the nucleus. Cells expressing
NiV M P93A displayed a somewhat intermediate pheno-
type with less pronounced filamentous structures and this
phenotype also corresponded to the partial budding-
defective phenotype (Fig. 4). Together, these results sup-Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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port the hypothesis that the NiV M-YPLGVG amino acid
motif plays an important role in NiV M budding, and that
it acts through a mechanism that is, in part, transferable to
other viruses.
NiV matrix budding is not dependent on VPS4A/B
The involvement of certain components of the cellular
MVB machinery has been demonstrated in several other
viral systems (reviewed in [30-32]). A powerful technique
that has helped facilitate the demonstration of these rela-
tionships has been the use of dominant-negative mutant
versions of one or more of the protein components of the
MVB complexes [31]. Dominant-negative (DN) mutants
of the paralogous MVB proteins VPS4A and VPS4B have
been shown to impair release of most viruses that use L-
domains to accomplish budding [32]. To determine
whether VPS4A has a functional role in NiV M VLP egress,
we evaluated NiV M release in the presence of VPS4A-
Site-directed proline mutagenesis Figure 1
Site-directed proline mutagenesis. (A) ClustalW alignment of the M proteins from Nipah virus (NiV), Hendra virus (HeV), 
Tupaia paramyxovirus (TPMV), measles virus (MeV), Sendai virus (SeV), Newcastle disease virus (NDV), and simian virus 5 
(SV5). Sequences of interest are boxed. Alignment was performed as described in the Methods. (B) Known L-domains are 
shown along with corresponding hypothetical L-domain sequences of NiV M (boxed in A). Underlined proline residues were 
mutated to alanine. (C) Mutant NiV M proteins, along with wild-type, were expressed in cells and released protein was pelleted 
through 10% sucrose. Proteins derived from the cell lysate (L) or culture supernatant (S) were immunoprecipitated using MAb 
F45G5 and analyzed by SDS-PAGE followed by autoradiography as described in the Methods.Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
Page 5 of 12
(page number not for citation purposes)
E228Q, a DN VPS4A mutant. SV5 VLP release, which is
significantly reduced in the presence of DN VPS4A [38],
was evaluated in parallel as a control. Cells were trans-
fected with expression plasmids for SV5 proteins (M, N, F,
and HN) or NiV M, along with 100 ng (per well) of plas-
mid containing Green Fluorescent Protein (GFP) fused to
either wild-type or DN VPS4A. The quantities of the SV5
plasmids used were as described by Schmitt and co-work-
ers [29] (N: 50 ng; M: 0.4 μg; F: 0.75 μg; HN: 0.75 μg), and
0.4 μg (per well) of NiV M was used along with empty vec-
tor for equivalent total DNA. Culture supernatants were
clarified, and VLPs were centrifuged through a 10%
sucrose cushion. Immunoprecipitation and SDS-PAGE
analysis of the pellet revealed that SV5 VLPs (as indicated
by M detection) were released in the presence of wild-type
VPS4A, but not in the presence of DN VPS4A, as expected
(Fig. 5A). In contrast, DN VPS4A had no effect on NiV M
release (Fig. 5A). The difference observed between SV5
and NiV M release was not due to unequal VPS4A expres-
sion, which was equivalent in each group (Fig. 5B). NiV M
release was similarly unaffected in the presence of DN
VPS4B or both DN VPS4A and DN VPS4B (data not
shown). These results suggest that NiV M VLP formation
is not dependent on functional VPS4 proteins.
NiV M sequence required for budding and possible late domain element Figure 2
NiV M sequence required for budding and possible late domain element. (A) NiV M mutants were constructed with 
single alanine substitution mutations in the YPLGVG sequence (underlined), or with the whole sequence deleted (dashes). (B) 
Wild-type NiV M and the mutants depicted in A were all expressed in cells and released protein was pelleted through a 20% 
sucrose cushion. Proteins derived from the cell lysate (L) or culture supernatant (S) were immunoprecipitated with MAb 
F45G5 and analyzed by SDS-PAGE followed by autoradiography. (C) Wild-type and mutant P93A HeV M were expressed in 
cells and a budding assay was performed as described in the Methods.Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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NiV sequence can rescue Ebola VP40-induced cellular morphology Figure 3
NiV sequence can rescue Ebola VP40-induced cellular morphology. (A) The L-domain and flanking sequence of VP40 
(underlined) was replaced with a sequence derived from NiV M (shaded) containing the YPLGVG sequence. (B) COS-1 cells 
were transfected with plasmids encoding VP40 wt, VP40 ΔPT/PY, or VP40-NiV. Cells were fixed 20–24 h post-transfection, 
permeablilized, and incubated with mouse anti-VP40 MAb followed by Alexa Fluor 488 donkey anti-mouse antibody and ana-
lyzed by confocal microscopy. The VP40-NiV immunofluorescence experiment was performed separately; all images are repre-
sentative.Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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Discussion
Previously, we observed that the M protein of NiV was
capable of budding and forming VLPs when expressed
independently in cell culture. In the present study we
sought to characterize the NiV M protein further and
explore whether NiV M possessed a classic L-domain
motif that was required for efficient budding. Noting that
all well-defined L-domains contain at least one proline
residue, we initiated a mutagenesis strategy whereby indi-
vidual proline residues in NiV M were mutated to alanine.
We identified 3 sequences (4 proline residues, total) of
interest because of their similarity to known L-domain
motifs, or close alignment to the SV5 FPIV motif. Using
this mutagenesis approach coupled with our NiV VLP
budding assay, we identified one particular M mutant
(P93A) that was defective in budding. To confirm this
observation and further characterize the surrounding
amino acids, we targeted the YPLGVG sequence within the
M protein and additional alanine mutants were made
(Y92A and L94A), as well as a deletion mutant (Δ92–97),
which were then tested for budding ability. Whereas a low
level of P93A release could sometimes be detected, we
found the other YPLGVG mutants were completely defec-
tive in budding. This sequence motif is conserved in HeV
and a P93A mutation in HeV M resulted in diminished
budding ability.
To determine whether this sequence has transferable
activity, the L-domain motifs and flanking residues of
Ebola VP40 were replaced with the YPLGVG motif along
with the appropriate NiV M flanking amino acids.
Although budding of the VP40-NiV M recombinant con-
taining the YPLGVG motif was not significantly restored,
staining with anti-VP40 mAb and immunofluorescence
Cellular morphology of NiV M-expressing cells is dependent on YPLGVG Figure 4
Cellular morphology of NiV M-expressing cells is dependent on YPLGVG. COS-1 cells were transfected with WT, 
P93A, or Δ92–97 NiV M plasmids and treated as described in Fig. 3B and the Methods except MAb F45G5 (anti-NiV M) was 
used, and cells were visualized by fluorescent microscopy.Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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microscopy revealed that cells expressing the VP40-NiV M
recombinant containing YPLGVG displayed a morphol-
ogy consistent with those expressing wild-type VP40 that
was characterized by fragmented and branching filamen-
tous structures. Similar morphology was observed for cells
expressing wild-type NiV M, whereas mutation or deletion
of the YPLGVG motif resulted in either less pronounced or
an absence of the filamentous structures accompanied by
nuclear localization of the mutant M protein. These data
suggest that the YPLGVG sequence motif is important for
proper NiV M cellular location and budding and can par-
tially substitute for the native VP40 L-domain sequence.
VPS4A and VPS4B are paralogous ATPases that are respon-
sible for disassembly of the Endosomal Sorting Complex
Required for Transport (ESCRT) complexes involved in
MVB formation, and mutations that destroy their ability
to bind or hydrolyze ATP result in the ability to domi-
nantly inhibit cellular VPS4A or VPS4B. These DN
mutants inhibited the budding and release of most viruses
that use L-domains and are thought to provide a method
of global inhibition of class E Vps proteins [30-32,50].
Notably, we found that NiV M budding and release was
unchanged in the presence of DN VPS4A, while in paral-
lel, SV5 VLP release was greatly reduced, in agreement
with a previous report [38]. Furthermore, NiV M protein
release was also unchanged in the presence of DN VPS4B,
or in the presence of both DN VPS4A and DN VPS4B, thus
eliminating the possibility that NiV M protein release was
accomplished by VPS4B or that the wild-type cellular par-
alogs were rescuing release. We also observed that NiV M
release is relatively insensitive to proteasome inhibition
and unaffected by AIP1/Alix over-expression (data not
shown), further suggesting that NiV M budding is inde-
pendent of MVB components [31].
We took note of the YPLGVG sequence motif because of
its similarity to the known L-domain YP(x)nL. This motif
was first discovered in the Gag p9 protein of equine infec-
tious anemia virus (EIAV) as YPDL [45] and then later
identified in the p6 domain of human immunodeficiency
virus type 1 (HIV-1) Gag protein (YPLTSL) [42]. Initial
characterization of this motif in EIAV determined that the
Y, P, and L residues were critical for virus particle budding;
however, the motif was designated YxxL because of the
similarity to the YxxL endocytosis motif, and it was
hypothesized that the EIAV motif interacted with cellular
endocytosis machinery [45]. However, it appears that
AIP1/Alix is the primary protein that interacts with this L-
domain, and the EIAV motif is now usually designated as
YP(x)nL or YPxL because the proline residue is critical for
AIP1/Alix binding and virus particle budding [30-32].
Both HIV-1 and EIAV Gag proteins contain a sequence just
downstream of the YP(x)nL motif that is also important
for AIP1/Alix binding, and it has been suggested that the
two motifs are actually a single motif that can be summa-
rized as (L) [F/Y]Px1–3LXX [I/L] [51].
Using the YxxL designation as a guide, Ciancanelli and
Basler identified 62-YMYL-65 as a sequence important for
NiV M budding [23]. Their study found that alanine muta-
tion of Y62, Y62 and L65, or deletion of the whole
sequence resulted in defective M protein budding, with
deletion mutants exhibiting nuclear localization. They
also established the functional rescue of L-domain-
mutant VP40 budding by appending the YMYL sequence
motif, with flanking elements to the C-terminus of VP40.
We attempted to use this observation as a control for our
experiments here by directly replacing the native VP40 L-
domain with the identical NiV sequence used in that
NiV M release is insensitive to VPS4A inhibition Figure 5
NiV M release is insensitive to VPS4A inhibition. (A) Cells were transfected with expression plasmids for SV5 N, M, F 
and HN, or NiV M, along with either wild-type or the dominant-negative VPS4A, followed by 35S-metabolic labeling. Released 
protein was pelleted through 10% sucrose, as described in the Methods, and proteins derived from cell lysates (L) and culture 
supernatants (S) were immunoprecipitated with either rabbit anti-SV5 polyclonal serum or MAb F45G5 (anti-NiV M) and ana-
lyzed by SDS-PAGE followed by autoradiography. (B) Expression of VPS4A was detected in cell lysates from the material ana-
lyzed in A by immunoprecipitation with rabbit polyclonal antiserum against GFP, followed by SDS-PAGE and autoradiography.Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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study, as we did with the present YPLGVG motif, rather
than appending it to the C-terminus. However, this con-
struct was also unable to restore budding of the L-domain-
mutant VP40 (data not shown). The reason for the differ-
ence is not known; however, L-domains can be context-
dependent, which may account for our differing result
[31,40-42]. Interestingly, the equivalent sequence in HeV
M is YMYM, and mutation of the NiV YMYL to the HeV
sequence does not appear to adversely affect NiV M
release (data not shown).
Based on their observation of nuclear localization of NiV
M YMYL mutant, Ciancanelli and Basler speculated that
NiV M contains competing trafficking signals, and that
disruption of targeting to the plasma membrane resulted
in the redirection of the protein to the nucleus [23].
Indeed, our observation of nuclear localization of the NiV
M YPLGVG motif deletion mutant used here would be in
agreement with this hypothesis, and we speculate that
both sequences interact with one or more proteins in a
common pathway, resulting in proper targeting of M.
However, the mechanistic roles of either of these
sequences in henipavirus budding remain to be clarified.
L-domains and their interactions with cellular MVB
machinery, most likely represent a subset of protein
domains involved in virus budding. An early observation
made regarding Gag truncation mutants of HIV-1, which
did not express the L-domain-containing p6 protein, was
the apparent tethering of budding virions to the cell sur-
face [31,52]. This phenotype appears to represent a defect
in the final step of virus-cell separation and suggests that
mechanisms other than those underlying L-domain func-
tion also play an important role in HIV-1 budding. In
addition, deletion of the Ebola virus overlapping L-
domains in VP40 results in a modest defect in replication
competent virus production and suggests that mecha-
nisms independent of MVB machinery may play a domi-
nant role in Ebola virus budding [53]. The NiV YPLGVG
sequence motif may facilitate budding of NiV M via inter-
actions with non-MVB-associated cellular proteins, which
enable the associated cellular morphology characterized
by extensive filamentous projections that is also seen with
VP40, by this alternative mechanism. The observation
that NiV M release is insensitive to DN VPS4 proteins and
proteasome inhibition lends some support to this inter-
pretation. However, vesicular stomatitis virus (VSV) has
been reported to be insensitive to DN VPS4A [44], and
EIAV is insensitive to proteasome inhibitors [54-56].
Thus, insensitivity to DN VPS4 proteins and proteasome
inhibitors may not be sufficient grounds to rule out L-
domain activity. Further, it also remains a formal possibil-
ity that the NiV M protein YPLGVG sequence motif failed
to rescue VP40 budding while restoring the filamentous
cellular morphology because of the context of the flanking
amino acids rather than a lack of intrinsic L-domain func-
tion.
Although studies with SeV have yielded conflicting results,
Gosselin-Grenet and co-workers failed to find a reduction
in SeV virion production in the presence of DN VPS4A or
during suppression of AIP1/Alix expression. These results
suggest that SeV budding also occurs independent of cel-
lular MVB proteins, and are in agreement with the present
observations on NiV M [47]. Chen and Lamb highlighted
the reported VPS4 independence of VSV, SeV, and influ-
enza virus and suggested that additional VPS4-independ-
ent viruses will serve as tools in uncovering the details of
these additional mechanisms of virus budding [50], and
our results suggest that NiV may also be a useful system to
explore such alternative mechanisms. Further characteri-
zation of the YPLGVG sequence and whether there are any
interactions with MVB cellular components in the context
of both VLPs and live virus will be needed to definitively
establish whether this element possesses classical L-
domain activity or functions through some alternative
mechanism.
Conclusion
Using a recombinant expression system the budding proc-
ess of the NiV M protein was examined and the amino
acid motif YPLGVG within the M protein was found to be
essential for M budding. Mutation or deletion of the
YPLGVG motif also resulted in nuclear localization of NiV
M. The transfer of the YPLGVG motif to an Ebola virus
VP40 L-domain mutant did not restore its budding effi-
ciency to wild type levels, but did restore the branched fil-
amentous cell morphology characteristic of VP40
expressing cells. NiV M expression also resulted in the
branched filamentous cell morphology, and YPLGVG
motif NiV M mutant did not. Unlike classic L-domain
containing proteins, we found no evidence of a role for
MVB proteins in henipavirus budding. The data here sug-
gest that whatever the specific role of the YPLGVG
sequence has in NiV budding it appears distinct from the
similar YP(x)nL sequence motif represented by EIAV. Fur-
ther investigation of henipavirus assembly and budding
may reveal a new mechanism of viral assembly and release
that could be applicable to other enveloped viruses or
have therapeutic implications.
Materials and methods
Cell lines
293T cells were maintained in Dulbecco's modified
Eagle's medium (Quality Biologicals, Gaithersburg, MD)
supplemented with 10% cosmic calf serum (Hyclone,
Logan, UT), 2 mM L-glutamine, and 100 units/ml penicil-
lin and streptomycin (Quality Biologicals, Gaithersburg,
MD) (DMEM-10). COS-1 cells were maintained in Dul-
becco's modified Eagle Medium Nutrient Mixture F-12Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
Page 10 of 12
(page number not for citation purposes)
(Ham) 1× (Invitrogen, Carlsbad, CA) supplemented as
described above (DMEM/F12-10).
Antibodies
The following antibodies were used in immunoprecipita-
tions: Monoclonal antibody (MAb) F45G5 (anti-M) [57]
was kindly provided by Jody Berry and Hana Weingartl
(National Centre for Foreign Animal Disease, Canadian
Food Inspection Agency). Rabbit anti-SV5 serum was
kindly provided by Robert Lamb (Northwestern Univer-
sity). Polyclonal sera from a rabbit immunized with
gamma-irradiated NiV and a MAb directed against VP40
were also used. Rabbit polyclonal antisera against the
green fluorescent protein (GFP) was purchased (Invitro-
gen, Carlsbad, CA).
Plasmids
The creation of pCAGGS-NiV M has been described previ-
ously [22]. The HeV M ORF was PCR amplified from
pCP436 (HeV M gene in pTD1) using the primers 5'-GTT-
TAAACCACCATGGATTTTAGTGTG (HEVMS) and 5'-
GTTTAAACTCACCCCTTTAGGATCTTC (HEVMAS). PCR
was done using Accupol DNA polymerase (PGS Scientifics
Corp., Gaithersburg, MD) with the following settings:
94°C for 5 min, then 25 cycles of 94°C for 1 min, 55°C
for 2 min, then 72°C for 3 min. The resulting PCR product
was ligated into pCRII-Blunt-TOPO (Invitrogen,
Carlsbad, CA), and then sub-cloned as a PmeI fragment
into the pCAGGS/MCS SmaI site. Amino acid changes
were introduced into NiV M and Ebola VP40 using stand-
ard PCR techniques or PCR site-directed mutagenesis
using the QuickChange II Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). pCAGGS-SV5 M, pCAGGS-SV5-
NP, pCAGGS-SV5-F, and pCAGGS-SV5-HN were kindly
provided by Robert Lamb. Wesley Sundquist (University
of Utah) kindly provided pEGFP-VPS4A-WT, pEGFP-
VPS4A-E228Q, pDsRed-VPS4B-WT, pDsRed-VPS4B-
E235Q.
Henipavirus matrix budding assay
NiV and HeV M VLP release was evaluated as previously
described [22], with minor modifications. Briefly, 293T
cells in 6-cm wells were transfected with 1 μg of each
expression plasmid (unless otherwise stated) in duplicate
using FuGene 6 transfection reagent (Roche, Indianapolis,
IN) according to the manufacturer's instructions. At 24 h
post transfection the culture medium was replaced with
methionine-cysteine-free minimal essential medium
(MEM) (Invitrogen, Carlsbad, CA) containing 2.5% dia-
lyzed fetal calf serum (Invitrogen, Carlsbad, CA) and 100
μCi/ml 35S-cys/met Redivue Promix (Amersham Pharma-
cia Biotech, Piscataway, NJ). At 20–24 h p.t. the cell cul-
ture medium was removed, clarified, and then centrifuged
through a cushion of 10% sucrose (w/vol) (unless stated
otherwise) in NTE (100 mM NaCl; 10 mM Tris-HCl, pH
7.5; 1 mM EDTA) at 200,000 × g for 2 h at 4°C. Cells were
removed by scraping and lysed in 200 μl lysis buffer (100
mM Tris-HCl, pH 8.0; 100 mM NaCl; 1.0% Triton-X 100)
containing Complete, Mini protease inhibitors at a 1×
concentration (Roche, Indianapolis, IN). Pelleted VLPs
were resuspended in 200 μl lysis buffer, and proteins
derived from lysates and supernatants were incubated
with the appropriate antibody overnight at 4°C, followed
by addition of Protein G-Sepharose (Amersham Bio-
sciences, GE Healthcare, Piscataway, NJ). Proteins were
analyzed by SDS-PAGE and autoradiography.
Ebola VP40 budding assay
The expression plasmids for Ebola VP40 and glycoprotein
GP have been generated as described previously [35,49].
A plasmid encoding the VP40-NiV protein chimera was
produced by introducing the putative L-domain of NiV in
place of the VP40 L-domain by PCR and inserted into vec-
tor pCAGGS using EcoRI and XhoI restriction endonucle-
ases. All introduced mutations were confirmed by
automated DNA sequencing. Human 293T cells in six-
well plates were transfected with 2 μg plasmid DNA of
Ebola GP plus 2 μg plasmid DNA of VP40WT or VP40-NiV
chimera by using the Lipofectamine reagent (Invitrogen,
Carlsbad, CA) and the protocol of the supplier. At 20–24
h post-transfection, proteins were metabolically labeled
with 150 μCi of 35S Met-Cys (Perkin-Elmer, Wellesley,
MA) for 5 h. Culture media was centrifuged at 2,500 rpm
for 10 min to remove cellular debris, layered onto a 20%
sucrose cushion in STE buffer (0.01 M Tris-HCl [pH 7.5],
0.01 M NaCl, 0.001 M EDTA [pH 8.0]), and centrifuged at
36,000 rpm for 2 h at 4°C. The resulting pellet containing
VLPs was suspended in 100 μl of STE buffer followed by
300 μl of RIPA buffer (50 mM Tris [pH 8.0], 150 mM
NaCl, 1.0% NP-40, 0.5% deoxycholate, 0.1% SDS) over-
night at 4°C. The VLPs were immunoprecipitated with the
anti-VP40 monoclonal antibody at 4°C overnight. The
immune complexes were then precipitated with 50 μl of a
20% protein A agarose bead suspension and analyzed by
SDS-PAGE. Protein bands were visualized by autoradiog-
raphy and quantified by phosphorimager analysis.
Indirect immunofluorescence
COS-1 cells were transfected with plasmids encoding
VP40WT, VP40ΔPT/PY or VP40-NiV proteins using Lipo-
fectamine and the protocol of supplier (Invitrogen,
Carlsbad, CA), or with plasmids encoding WT NiV M,
P93A, or Δ92–97 using FuGene 6 transfection reagent
(Roche, Indianapolis, IN). The cells were fixed with 4.0%
paraformaldehyde in 1× PBS (fresh-made) at room tem-
perature for 10 min at 20–24 h post-transfection, washed
three times with 1× PBS, permeabilized with 0.2% Triton
X-100 in 1× PBS on ice for 10 min, and washed three
times with 1× PBS. The cells were incubated with either
mouse anti-VP40 MAb (1:100), or F45G5 (anti-NiV M)Virology Journal 2008, 5:137 http://www.virologyj.com/content/5/1/137
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(3:100) in 3% BSA/PBS at 37°C in the dark for 30 min
and washed three times, and then incubated with Alexa
Fluor 488 donkey anti-mouse antibody (1:500) (Molecu-
lar Probes, Invitrogen, Carlsbad, CA) in 3% BSA/PBS at
37°C in the dark for 30 min. The cells were washed three
times with 1× PBS and one time with water, and then
mounted with Prolong antifade solution (Molecular
Probes, Invitrogen, Carlsbad, CA) and analyzed by confo-
cal immunofluorescent microscopy (VP40) or immun-
ofluorescent microscopy (NiV M).
Protein Sequence Alignment
ClustalW protein alignment was performed using the
ClustalW program of the European Bioinformatics Insti-
tute http://www.ebi.ac.uk/clustalw and the Jalview [58]
multiple alignment editor was used to view the ClustalW
alignment. Matrix gene sequences were derived from the
following GenBank accession numbers: Nipah virus
(NP_112025.1); Tupaia paramyxovirus (NP_054694.1);
measles virus (NP_056921.1); Sendai virus
(NP_056876.1); Newcastle disease virus (NP_071468.1);
simian virus 5 (YP_138514.1). The Hendra virus matrix
sequence was derived directly from pCP436.
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